Kineta, Inc. (NASDAQ:KANT) — Market Cap & Net Worth
Market Cap & Net Worth: Kineta, Inc. (KANT)
Kineta, Inc. (NASDAQ:KANT) has a market capitalization of $4.12 Million ($4.12 Million) as of April 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #32517 globally and #5491 in its home market, demonstrating a 31.80% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kineta, Inc.'s stock price $0.34 by its total outstanding shares 12265500 (12.27 Million).
Kineta, Inc. Market Cap History: 2016 to 2025
Kineta, Inc.'s market capitalization history from 2016 to 2025. Data shows change from $21.05 Billion to $4.12 Million (-56.98% CAGR).
Kineta, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kineta, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8.18x
Kineta, Inc.'s market cap is 8.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.46 Billion | $10.49 Million | -$8.05 Million | 139.17x | N/A |
| 2021 | $254.14 Million | $9.09 Million | -$11.82 Million | 27.96x | N/A |
| 2022 | $77.89 Million | $1.04 Million | -$63.41 Million | 74.82x | N/A |
| 2023 | $44.52 Million | $5.44 Million | -$14.10 Million | 8.18x | N/A |
Competitor Companies of KANT by Market Capitalization
Companies near Kineta, Inc. in the global market cap rankings as of April 19, 2026.
Key companies related to Kineta, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #188 globally with a market cap of $111.94 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #299 globally with a market cap of $77.99 Billion USD.
- UCB SA (BR:UCB): Ranked #456 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx SE (SA:A1RG34): Ranked #457 globally with a market cap of $51.73 Billion USD ( R$263.66 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #188 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $111.94 Billion | $441.20 |
| #299 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $77.99 Billion | $750.57 |
| #456 | UCB SA | BR:UCB | $51.74 Billion | €263.90 |
| #457 | argenx SE | SA:A1RG34 | $51.73 Billion | R$169.59 |
Kineta, Inc. Historical Marketcap From 2016 to 2025
Between 2016 and today, Kineta, Inc.'s market cap moved from $21.05 Billion to $ 4.12 Million, with a yearly change of -56.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $4.12 Million | -4.00% |
| 2024 | $4.29 Million | -90.36% |
| 2023 | $44.52 Million | -42.83% |
| 2022 | $77.89 Million | -69.35% |
| 2021 | $254.14 Million | -82.59% |
| 2020 | $1.46 Billion | -62.72% |
| 2019 | $3.92 Billion | -29.63% |
| 2018 | $5.56 Billion | -44.43% |
| 2017 | $10.01 Billion | -52.45% |
| 2016 | $21.05 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 18th, 2026 the market cap of Kineta, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.12 Million USD |
| MoneyControl | $4.12 Million USD |
| MarketWatch | $4.12 Million USD |
| marketcap.company | $4.12 Million USD |
| Reuters | $4.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kineta, Inc.
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combinati… Read more